Yahoo · Sep 29, 2026
Inventiva (IVA) Q2 2026 Earnings Call Transcript
Lanifibranor Phase III results expected Q4 2026, potential FDA submission H1 2027.
IV
NASDAQ · IVA
Inventiva S.A.
Healthcare · Biotechnology
$3.46
Up+$0.10 (+2.89%)
Updated Oct 2, 2026, 8:27 PM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 233.4M
- P/E ratio
- -1.32
- Dividend yield
- 0.00%
- 52-week range
- $3.11 – $7.98
- Volume
- 5.32M
- Avg. volume
- 247.07K
Price performance · IVA
IVA price history
1M range · 0 trading sessions · Daily adjusted prices
IVA does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest IVA news
The latest Smart Investors Daily articles mentioning IVA.
Stock researchCompany · Overview
Company
Market Activity
Research & News
IVA research
Overview
Company profile and research snapshot.
Company profile
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $15.33
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 16, 2026 | PIPER SANDLER COMPANIES | Overweight | — |
| Sep 15, 2026 | GUGGENHEIM SECURITIES LLC | Buy | — |
| Sep 3, 2026 | KBC SECURITIES | Buy | — |
| Aug 13, 2026 | CANTOR FITZGERALD | Overweight | — |
| Aug 1, 2026 | TD COWEN | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Sep 29, 2026
Canaccord Genuity Maintains Buy on Inventiva, Raises Price Target to $21
Canaccord Genuity analyst Edward Nash maintains Inventiva (NASDAQ:IVA) with a Buy and raises the price target from $20 to $21.
Yahoo · Sep 28, 2026
Inventiva SA (IVEVF) (H1 2026) Earnings Call Highlights: Lanifibranor Nears Phase 3 Readout ...
Inventiva SA (IVEVF) reported EUR233.9 million in cash and reaffirmed Q4 2026 top-line NATIV3 data for its MASH therapy lanifibranor, keeping a potential NDA submission on track for H1 2027.
SeekingAlpha · Sep 28, 2026
Inventiva S.A. (IVA) Q2 2026 Earnings Call Transcript
Inventiva S.A. (IVA) Q2 2026 Earnings Call September 28, 2026 8:00 AM EDTCompany ParticipantsDavid NikodemAndrew Obenshain - Chief Executive OfficerJason...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
